Nuvalent, Inc. is a clinical-stage biopharmaceutical company developing novel kinase inhibitors targeting specific mutations in non-small cell lung cancer (NSCLC). Despite promising clinical data and multiple FDA Breakthrough Therapy designations for its lead assets — particularly zidesamtinib and neladalkib — the company remains unprofitable with widening operating losses and negative cash flow as it prepares for potential commercialization. Supported by robust equity funding and over $260 million in year-end cash equivalents, Nuvalent faces typical biotech risks including regulatory hurdles, competitive oncology markets, and reimbursement uncertainties. Its financial runway extends into 2028, but future capital raises or partnerships may be needed to complete late-stage development and support launch efforts.